All In Biotech

Drug Trial Radar · NCT03910673

Intravenous Fosfomycin Pharmacokinetics Study

A Phase 1 Safety and Intrapulmonary Pharmacokinetics Study of ZTI-01 (Intravenous Fosfomycin Disodium) in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Oct 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

39

Actual

Start

Jun 27, 2019

Primary completion

Dec 17, 2020

Study completion Dec 17, 2020

Sponsor

Sponsor type
NIH
First posted
Apr 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, multiple-dose trial conducted at a single center. The treatment period will consist of three 6 g doses (18 g) of ZTI-01 as a 1-hour intravenous (IV) infusion (+10 minute window). A total of 30 enrolled subjects will be randomized to undergo a single standardized bronchoscopy with bronchoalveolar lavage (BAL) at one of five sampling times. A total of 6 subjects will be assigned to each BAL-sampling time. Up to ten additional enrolled subjects will act as alternates to obtain 30 evaluable subjects. An evaluable subject is defined as a subject who receives all doses of ZTI-01, undergoes BAL at the randomized sampling timepoint with BAL return volume adequate for testing, and undergoes at least the one blood sampling timepoint that is concurrent with the assigned BAL sampling timepoint, with blood sampling volume that is adequate for testing. The objectives of the study are to assess safety and pharmacokinetics (PK) for a multiple dose regimen of IV-infused ZTI-01.

Conditions

  • Bacterial Infection
  • Multiple-drug Resistance
  • Pathogen Resistance

Interventions

  • Fosfomycin disodiumDrug

    Fosfomycin (a phosphonic acid derivative) formulated as a disodium salt.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Concentration-time Curve (AUC 0-8 and AUC 0-inf ) of ZTI-01Time frame: Day 1 to Day 2
  2. Clearance (CL) of ZTI-01Time frame: Day 2
  3. Intrapulmonary Pharmacokinetics of ZTI-01Time frame: Day 2
  4. Maximum Measured Plasma Concentration (Cmax) of ZTI-01Time frame: Day 1 to Day 2
  5. Number of Participants Experiencing Abnormal Clinical Chemistry Laboratory AssessmentsTime frame: Day 1 to Day 2
  6. Number of Participants Experiencing Abnormal Clinical Hematology Laboratory AssessmentsTime frame: Day 1 to Day 2
  7. Number of Participants Experiencing Abnormal Clinical Coagulation Laboratory AssessmentsTime frame: Day 1 to Day 2
  8. Number of Participants Experiencing Abnormal Clinical Urinalysis Laboratory AssessmentsTime frame: Day 1 to Day 2
  9. Number of Participants Experiencing Abnormal Physical Examination FindingsTime frame: Day 1 to Day 2
  10. Number of Participants Experiencing Abnormal Vital Sign MeasurementsTime frame: Day 1 to Day 2
  11. Number of Participants Experiencing Adverse Events (AEs)Time frame: Day 1 to Day 3
  12. Number of Participants With Prolonged QTc, PR, or QRS Intervals in Electrocardiogram (ECG) ReadingsTime frame: Day 1 to Day 2
  13. Terminal Elimination Half-life (t1/2) of ZTI-01Time frame: Day 2
  14. Terminal-phase Elimination Rate Constant (Lambdaz) of ZTI-01Time frame: Day 2
  15. Time to Peak Concentration (Tmax) of ZTI-01Time frame: Day 1 to Day 2
  16. Volume of Distribution at Steady State (Vss) of ZTI-01Time frame: Day 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Duke Human Vaccine Institute - Duke Vaccine and Trials Unit

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.